Growth hormone secretagogues: Physiological role and clinical utility

Trends in Endocrinology and Metabolism

Volumn 10, Issue 1, 1999, Pages 30-38

  Casanueva, Felipe F ^a   Dieguez, Carlos ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 HYDROXYPROPYLAMINO) 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; CAPROMORELIN; GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; IBUTAMOREN; IPAMORELIN; MK 0751; NNC 26 0703; PRALMORELIN; UNCLASSIFIED DRUG;

DRUG STRUCTURE; GENE EXPRESSION; GENE MUTATION; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HUMAN CELL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MOLECULAR MODEL; PRIORITY JOURNAL; REVIEW;

EID: 0032999643     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(98)00116-7     Document Type: Review

References (71)

1. Bowers C.Y., Chang J., Momany F.A., Folkers K. Effect of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. MacIntyre G., Szelke H. Molecular Endocrinology. 1977;287-292 Elsevier, North Holland.
2. Momany F.A., Bowers C.Y. Computer-assisted modelling of xenobiotic growth hormone secretagogues. Bercu B.B., Walker R.F. Growth Hormone Secretagogues. 1996;73-83 Springer-Verlag.
3. Bowers C.Y., Sartor A.A., Reynolds D.G., Badger T.A.M. On the actions of the growth hormone-releasing hexapeptide, GHRP-6. Endocrinology. 128:1991;2027-2035.
4. Korbonits M., Grossman A. Growth hormone-releasing peptide and its analogues: novel stimuli to growth hormone release. Trends Endocrinol. Metab. 6:1995;43-49.
5. Howard A.D.et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 273:1996;974-977.
6. Bowers C.Y. Xenobiotic growth hormone secretagogues: growth hormone releasing peptides. Bercu B.B., Walker R.F. Growth Hormone Secretagogues. 1996;9-28 Springer-Verlag.
7. Deghenghi R., Cananzi M.M., Torsello A., Battisti C., Muller E.E., Locatelli V. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 54:1994;1321-1328.
8. McDowell R.S.et al. Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation. Proc. Natl. Acad. Sci. U. S. A. 92:1995;11165-11169.
9. Patchett A.A.et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7001-7005.
10. Carpino P.A.et al. Discovery of the novel pyrazolidinone-piperidine GH secretagogue. Proceedings of 80th Annual Meeting Endocrine Society, New Orleans, USA. 1998;Abstr P2-191.
11. Rasmussen M.H., Sogaard B., Ynddal L., Groes L., Helmgaard L., Nordholm L. Ipamorelin - a very potent novel growth hormone secretagogue. Proceedings of 80th Annual Meeting Endocrine Society, New Orleans, USA. 1998;Abstr P1-185.
12. Brosnan-Cook M.et al. Iontophoretic delivery of ipamorelin, a growth hormone secretagogue. Proceedings of 80th Annual Meeting Endocrine Society, New Orleans, USA. 1998;Abstr P1-186.
13. Muccioli G.et al. Tissue distribution of GHRP receptors in humans. Proceeding of 6th European Congress of Endocrinology, Sevilla, Spain. 1998;Abstr OR15-7.
14. Bercu B.B., Yang S-W., Masuda R., Walker R.F. Role of selected endogenous peptides in growth hormone releasing hexapeptide (GHRP) activity: analysis of GHRH, TRH and GnRH. Endocrinology. 130:1992;2579-2586.
15. Chen C., Wu D., Clarke I.J. Signal transduction systems employed by synthetic GH-releasing peptides in somatotrophs. J. Endocrinol. 148:1996;381-386.
16. Frohman L.A., Downs T.R., Chomczynski P. Regulation of growth hormone secretion. Front. Neuroendocrinol. 13:1992;344-405.
17. Goth M.I., Lyons C.E., Canny B.J., Thorner M.O. Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology. 130:1992;939-944.
18. Codd E.E.C., Shu A.I.L., Walker R.F.C. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology. 28:1989;1139-1144.
19. Bowers C.Y., Reynolds D.G., Durham D., Barrera C.M., Pezzoli S.S., Thorner M.O. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J. Clin. Endocrinol. Metab. 70:1990;975-982.
20. Peñalva A., Carballo A., Pombo M., Casanueva F.F., Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine or hypoglycemia on GHRP-6-induced GH secretion in man. J. Clin. Endocrinol. Metab. 76:1993;168-171.
21. Smith R.G.et al. Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. 18:1997;621-645.
22. Dickson S.L., Leng G., Dyball R.E.J., Smith R.G. Central actions of peptide and non-peptide growth hormone secretagogues in the rat. Neuroendocrinology. 61:1995;36-43.
23. Dickson S.I., Luckman S.M. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleous following systemic injection of the GH secretagogue GH-releasing peptide-6. Endocrinology. 138:1997;771-777.
24. 2 (GHRP-6)-induced GH secretion in the rat. Neuroendocrinology. 57:1993;247-256.
25. Popovic V., Damjanovic S., Micic D., Djurovic M., Dieguez C., Casanueva F.F. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J. Clin. Endocrinol. Metab. 80:1995;942-947.
26. Pombo M., Barreiro J., Peñalva A., Peino R., Dieguez C., Casanueva F.F. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J. Clin. Endocrinol. Metab. 80:1995;3180-3184.
27. Guillaume V.et al. GH-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology. 135:1994;1073-1076.
28. Torsello A.et al. Mechanism of action of hexarelin. I. Growth hormone releasing activity in the rat. Eur. J. Endocrinol. 135:1996;481-488.
29. Peñalva A., Pombo M., Carballo A., Barreiro J., Casanueva F.F., Dieguez C. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clin. Endocrinol. 38:1993;87-91.
30. Robinson B.M., Friberg R.D., Bowers C.Y., Barkan A.L. Acute growth hormone (GH) response to GH-releasing hexapeptide in humans is independent of endogenous GH-releasing hormone. J. Clin. Endocrinol. Metab. 75:1992;1121-1124.
31. Jaffe C.A., Ho P.J., Demott F-R., Bowers C.Y., Barkan A.L. Effect of prolonged growth hormone (GH)- releasing peptide infusion on pulsatile GH secretion in normal men. J. Clin. Endocrinol. Metab. 77:1993;1641-1647.
32. Micic D., Popovic V., Kendereski A., Peino R., Dieguez C., Casanueva F.F. The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man. Clin. Endocrinol. 45:1996;543-551.
33. Arvat E.et al. Modulation of growth hormone-releasing activity of hexarelin in man. Neuroendocrinology. 61:1995;51-56.
34. 2 on GH release in conscious, freely moving male rats. Neuroendocrinology. 63:1996;198-206.
35. Ghigo E.et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, and oral administration in man. J. Clin. Endocrinol. Metab. 78:1994;693-698.
36. Copinschi G.et al. Effects of a 7-day treatment with a novel orally active growth hormone secretagogue MK-0677, on 24-hour growth hormone profiles, insulin-like growth factor-1, and adrenocortical function in normal young men. J. Clin. Endocrinol. Metab. 81:1996;2776-2782.
37. Huhn W.C., Hartman M.L., Pezzoli S.S., Thorner M.O. Twenty-four hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to subsequent GHRP bolus. J. Clin. Endocrinol. Metab. 76:1993;1202-1208.
38. Popovic V., Micic D., Djurovic M., Obradovic S., Casanueva F.F., Dieguez C. Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa. Clin. Endocrinol. 46:1997;539-543.
39. Peino R., Cordido F., Peñalva A., Alvarez C.V., Dieguez C., Casanueva F.F. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli. J. Clin. Endocrinol. Metab. 81:1996;909-913.
40. Ghigo E., Arvat E., Muccioli G., Camanni F. Growth hormone-releasing peptides. Eur. J. Endocrinol. 136:1997;445-460.
41. Giustina A.et al. Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. J. Endocrinol. 146:1995;227-232.
42. Ramos-Diaz J.C., Pimentel-Filho F., Reis A.F., Lengyel A.M.J. Different growth hormone (GH) responses to GH-releasing peptide and GH-releasing hormone in hyperthyroidism. J. Clin. Endocrinol. Metab. 81:1996;1343-1346.
43. Loche S.et al. The growth hormone response to hexarelin in children: reproducibility and effect of sex steroids. J. Clin. Endocrinol. Metab. 82:1997;861-864.
44. Shimon I., Yan X., Melmed S. Human fetal pituitary expresses functional growth hormone-releasing peptide receptors. J. Clin. Endocrinol. Metab. 83:1998;174-178.
45. Pombo M., Barreiro J., Peñalva A., Mallo F., Casanueva F.F., Dieguez C. Plasma growth hormone response to growth hormone-releasing hexapeptide (GHRP-6) in children with short stature. Acta Paediatr. 84:1995;904-908.
46. Laron Z., Frenkel J., Deghenghi R., Anin S., Klinger B., Silbergeld A. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin. Endocrinol. 43:1995;631-635.
47. Hartman M.L., Farello G., Pezzoli S.S., Thorner M.O. Oral administration of growth hormone (GH)-releasing peptide administration stimulates GH secretion in normal men. J. Clin. Endocrinol. Metab. 74:1992;1378-1384.
48. Gertz B.J.et al. Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. J. Clin. Endocrinol. Metab. 77:1993;1393-1397.
49. Micic D., Popovic V., Kendereski A., Macut D., Casanueva F.F., Dieguez C. Growth hormone secretion after the administration of GHRP-6, or GHRP-6 plus GHRH does not decline in late adulthood. Clin. Endocrinol. 42:1995;191-194.
50. Micic D., Popovic V., Doknic M., Macut D., Dieguez C., Casanueva F.F. Preserved growth hormone (GH) secretion in aged and very old subjects after testing with the combined stimulus GH-releasing hormone plus GH-releasing hexapeptide-6. J. Clin. Endocrinol. Metab. 83:1998;2569-2572.
51. Dieguez C., Casanueva F.F. Influence of metabolic substrates and obesity on growth hormone secretion. Trends Endocrinol. Metab. 6:1995;55-59.
52. Cordido F., Peñalva A., Dieguez C., Casanueva F.F. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J. Clin. Endocrinol. Metab. 76:1993;819-823.
53. Leal A., Pumar A., Garcia E., Dieguez C., Casanueva F.F. Blocked growth hormone discharge after the combined administration of GHRH plus GHRP-6 in patients with Cushing's syndrome. Clin. Endocrinol. 41:1994;649-654.
54. Popovic V., Damjanovic S., Micic D., Petakov M., Dieguez C., Casanueva F.F. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH- releasing peptide-6. J. Clin. Endocrinol. Metab. 79:1994;456-460.
55. Popovic V.et al. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy. Clin. Endocrinol. 48:1998;103-108.
56. de Zegher F.et al. Postpartum hyperprolactinemia and hyporesponsiveness of growth hormone (GH) to GH-releasing peptide. J. Clin. Endocrinol. Metab. 83:1998;103-106.
57. Cuneo R.C., Salomon F., McGauley G.A., Sonksen P.H. The growth hormone deficiency syndrome in adults. Clin. Endocrinol. 37:1989;387-397.
58. Jorgensen J.O.L.et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. i:1989;1221-1224.
59. Shalet S.M., Toogood A., Rahim A., Brennan B.M.D. The diagnosis of growth hormone deficiency in children and adults. Endocr. Rev. 19:1998;203-223.
60. Leal A., Garcia E., Astorga R., Casanueva F.F., Dieguez C. Growth hormone (GH) responses to the combined administration of GH-releasing hormone plus GH-releasing peptide 6 in adults with GH deficiency. Eur. J. Endocrinol. 132:1995;712-715.
61. Massoud A.F., Hindmarsh P.C., Brook D.G.D. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J. Clin. Endocrinol. Metab. 81:1996;4338-4341.
62. Raun K.et al. Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol. 139:1998;552-561.
63. Prager D., Melmed S. Somatotroph insulin-like growth factor 1 signalling. Ann. New York Acad. Sci. 692:1993;102-112.
64. Wells T., Flavell D.M., Wells S.E., Carmignac D.F., Robinson I.C.A.F. Effects of growth hormone secretagogues in the transgenic growth-retarded (Tgr) rat. Endocrinology. 138:1997;580-587.
65. Chapman I.M.et al. Stimulation of the growth hormone (GH)-insulin like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J. Clin. Endocrinol. Metab. 81:1996;4249-4257.
66. Van den Berghe G.et al. Neuroendocrinology of prolongued critical illness: effects of exogenous thyrotropin releasing hormone and its combination with growth hormone secretagogues. J. Clin. Endocrinol. Metab. 83:1998;309-319.
67. Murphy M.G.et al. MK-677 an orally active growth hormone secretagogue reverses diet-induced catabolism. J. Clin. Endocrinol. Metab. 83:1998;320-325.
68. Kirk S.E.et al. Effect of obesity and feeding on the growth hormone (GH) response to the GH secretagogue L-692,429 in young men. J. Clin. Endocrinol. Metab. 82:1997;1154-1159.
69. Svensson J.et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J. Clin. Endocrinol. Metab. 83:1998;362-369.
70. Okada K., Ishii S., Minayami S., Sugihara H., Shibasaki T., Wakabayashi I. Intracerebroventricular administration of the growth hormone-releasing peptide KP-102 increases food intake in free-feeding rats. Endocrinology. 137:1996;5155-5158.
71. Rossoni G., Gennaro De V., Bernareggi M., Poovani G.L., Muller E.E., Berti F. Protectant activity of hexarelin or growth hormone against post-ischemic ventricular dysfunction in hearts from aged rats. J. Cardiovasc. Pharmacol. 32:1998;260-265.